STOCK TITAN

Establishment Labs to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global leader in women's health technology, has announced that CEO Juan José Chacón-Quirós will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 PM ET. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible afterward. Establishment Labs specializes in breast aesthetics and reconstruction, offering innovative Motiva Implants with over 1.8 million units delivered since 2010 across 80 countries.

Positive
  • None.
Negative
  • None.

SANTA BARBARA, Calif.--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 1:30pm Eastern Time.

A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following the completion of the event.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, more than 1.8 million Motiva Implants® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora® tissue expander and Motiva MIA®, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant® and began a clinical trial to support regulatory approval in the United States. Motiva Implants® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at www.establishmentlabs.com.

Investor/Media Contact:

Raj Denhoy

415-828-1044

rdenhoy@establishmentlabs.com

Source: Establishment Labs Holdings Inc.

FAQ

When is the presentation by Establishment Labs at the J.P. Morgan Healthcare Conference?

Juan José Chacón-Quirós will present on January 11, 2022, at 1:30 PM ET.

Where can I watch the Establishment Labs presentation?

The presentation will be available via live webcast on the Establishment Labs investor relations website.

What is the focus of Establishment Labs?

Establishment Labs focuses on improving women's health and wellness, mainly in breast aesthetics and reconstruction.

How many Motiva Implants has Establishment Labs delivered?

Establishment Labs has delivered over 1.8 million Motiva Implants since 2010.

In how many countries are Motiva Implants sold?

Motiva Implants are sold in over 80 countries worldwide.

Establishment Labs Holdings Inc.

NASDAQ:ESTA

ESTA Rankings

ESTA Latest News

ESTA Stock Data

1.12B
25.28M
11.28%
98.89%
17.16%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
ALAJUELA